ELB 139

Drug Profile

ELB 139

Alternative Names: ELB-139

Latest Information Update: 23 Aug 2007

Price : $50

At a glance

  • Originator elbion NV
  • Class Anxiolytics
  • Mechanism of Action GABA A receptor agonists; Serotonin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders

Most Recent Events

  • 05 Dec 2006 4AZA Bioscience has merged with elbion to form elbion NV
  • 12 Dec 2005 Data presented at the 35th Annual Meeting of the Society for Neuroscience (SfN-2005) have been added to the adverse events, and Anxiety disorders and Psychotic disorders pharmacodynamics sections ,,,
  • 24 Nov 2005 Data presented at the 18th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2005) have been added to the Anxiety disorders and Epilepsy and movement disorders pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top